The proglucagon-derived peptide family consists of three highly related peptides, glucagon and the glucagon-like peptides GLP-1 and GLP-2. Although the biological activity of glucagon as a counter-regulatory hormone has been known for almost a century, studies conducted over the past decade have now also elucidated important roles for GLP-1 as an antidiabetic hormone, and for GLP-2 as a stimulator of intestinal growth. In contrast to pancreatic glucagon, the GLPs are synthesized in the intestinal epithelial L cells, where they are subject to the influences of luminal nutrients, as well as to a variety of neuroendocrine inputs. In this review, we will focus on the complex integrative mechanisms that regulate the secretion of these peptides from L cells, including both direct and indirect regulation by ingested nutrients.
Introduction
Glucagon and the glucagon-like peptides GLP-1 and GLP-2 play important roles in the maintenance of energy homeostasis through effects on nutrient digestion, absorption, and storage, as well as mobilization (Kieffer and Habener 1999; Drucker 2001 Drucker , 2002 L'Heureux and Brubaker 2001; MacDonald et al. 2002; Holst 2002 ). In contrast to glucagon, which is produced by pancreatic A cells, the GLPs are synthesized and secreted by enteroendocrine cells localized in the intestinal epithelium (Eissele et al. 1992) . Recent studies have established that the regulation of GLP-1 and GLP-2 secretion is highly complex, involving direct effects of ingested nutrients, as well as indirect effects through neural and endocrine pathways. The focus of this review will be on the mechanisms that regulate secretion of GLP-1 and GLP-2 from the intestine.
Synthesis and biological actions of GLP-1 and GLP-2
The proglucagon gene is expressed at high levels in pancreatic A cells and intestinal L cells, as well as at lower levels in selected neurons in the hypothalamus and brain stem (Lee et al. 1990 ). The structure of proglucagon suggests that it may have arisen through several gene duplication events ( Fig. 1) , with GLP-1 and GLP-2 exhibiting approximately 50% sequence identity to glucagon (White and Saunders 1986) . It is noteworthy that the receptors for these peptides are also highly homologous, belonging to the class 2 family of G-protein-coupled, 7-transmembrane-domain receptors (Brubaker and Drucker 2002) . This high degree of sequence conservation for both ligand and receptor suggests that the glucagon family of peptides has played an important role in physiology throughout evolution (Irwin 2002) .
Post-translational processing of proglucagon by the prohormone convertase (PC) family of enzymes liberates a unique, tissue-specific profile of proglucagon-derived peptides (PGDPs) (Fig. 1) . In pancreatic A cells, PC2, and possibly another yet-to-be-identified enzyme, cleaves proglucagon at consensus pairs of basic amino acids flanking the sequence of glucagon and liberates this peptide as well as the biologically inactive fragments, glicentin-related pancreatic peptide, intervening peptide-1, and the major proglucagon fragment. In contrast, cleavage at similar consensus sites by the enzyme PC1/3 is both sufficient and necessary for the liberation of GLP-1 and GLP-2 from proglucagon in L cells (Rothenberg et al. 1995; Rouille et al. 1995; Dhanvantari et al. 1996) . Thus, processing of proglucagon in the intestine generates equimolar amounts of GLP-1 and GLP-2, and sampling of the mesenteric circulation draining the intestinal bed has confirmed that these PGDPs are secreted in a 1:1 ratio (Orskov et al. 1986 ). It should be noted that a number of additional peptides are also produced during the post-translational processing of proglucagon in the intestine, including glicentin, oxyntomodulin, and intervening peptide-2 (Fig. 1) . Although the physiological importance of these peptides remains unclear, they are also cosecreted with GLP-1 and GLP-2, and measurement of the circulating levels of any of these peptides can be used as an indicator of L-cell secretory activity.
GLP-1 was first reported in 1987 to be a potent stimulator of glucose-dependent insulin release (Mojsov et al. 1987) , with physiological levels of the peptide increasing insulin secretion by twofold at 5 mmol glucose/L and by greater than fivefold at 7 mmol glucose/L (Vilsboll et al. 2003) . Since that time, numerous studies using GLP-1 agonists, antagonists, and immunoneutralization, as well as genetic loss-of-and gain-of-function rodent models have demonstrated that GLP-1 enhances postprandial insulin secretion, thereby reducing fed glycemia (Drucker 2002; MacDonald et al. 2002; Holst 2002) . Importantly, GLP-1 possesses several additional biological actions that are complementary to this incretin effect, including inhibition of glucagon release and gastric emptying, enhancement of peripheral insulin sensitivity, and induction of satiety (Willms et al. 1996; Toft-Nielsen et al. 1999; Lovshin et al. 2001; Prigeon et al. 2003) . These findings are consistent with the demonstration of GLP-1 receptor expression in β cells, the stomach, and the brain (Campos et al. 1994) . Furthermore, GLP-1 has also recently been demonstrated to be trophic to pancreatic β cells, increasing functional islet mass through stimulation of islet neogenesis and β-cell proliferation, in addition to inhibition of β-cell apoptosis (Xu et al. 1999; Wang and Brubaker 2002) . When taken together, these pleiotropic actions of GLP-1 make this hormone a natural defense against hyperglycemia. Indeed, acute administration of GLP-1 to patients with type 2 diabetes lowers fasting and postprandial glycemia (Willms et al. 1996) , while chronic treatment not only reduces glycemia, but also HbA1c levels and body weight (Zander et al. 2002) . GLP-1 and its analogs are therefore currently being used in clinical trials for the treatment of patients with type 2 diabetes. Furthermore, it is well established that GLP-1 has an extremely short half-life in the circulation because of degradation by the ubiquitous enzyme dipeptidylpeptidase IV (DP IV) (cleaves off the first two N-terminal amino acids) (Kieffer et al. 1995) , and recent studies with DP-IV-resistant analogs of GLP-1, as well as with inhibitors of DP IV, have now demonstrated that these may be promising approaches to increase the levels of bioactive GLP-1 in patients with type 2 diabetes (Drucker 2003) . More detailed reviews on the biological actions of GLP-1 have been written by Drucker (2002) , MacDonald et al. (2002), and Holst (2002) .
In contrast to the wide-ranging effects of GLP-1, the peripheral actions of GLP-2 are largely restricted to the intestinal mucosa. Chronic administration of GLP-2 to rodents enhances small and large intestinal weight through increased crypt cell proliferation and decreased villous apoptosis (Drucker et al. 1996; Tsai et al. 1997; Brubaker et al. 1997b) . GLP-2 treatment also increases the digestive and absorptive capacity of the gut (Brubaker et al. 1997b; Au et al. 2002) , and enhances barrier function through decreased permeability (Benjamin et al. 2000) . Furthermore, GLP-2 stimulates intestinal growth and increases intestinal function in animal models of intestinal loss or damage (Scott et al. 1998; Boushey et al. 1999; L'Heureux and Brubaker 2003; Guan et al. 2003) , as well as in patients with short bowel syndrome (Jeppesen et al. 2001 ). Finally, GLP-2 has been reported to reduce satiety when administered directly into the brain, although the physiological importance of this finding is unclear (Lovshin et al. 2001) . Nonetheless, the known biological actions of GLP-2 are consistent with the demonstration that expression of the GLP-2 receptor is localized to the gastrointestinal tract and hypothalamus (Lovshin et al. 2001) , although the exact cells that express this receptor in the gut remain the subject of some controversy. Although GLP-2 has only recently been recognized as a trophic hormone for the intestinal tract, the early success of the one limited study in humans (Jeppesen et al. 2001 ) has already led to clinical trials to examine the potential of this peptide for the treatment of human intestinal insufficiency. Furthermore, consistent with the sequence homology among the glucagon-like peptides, GLP-2 is also degraded in the circulation by DP IV (Tavares et al. 2000) . Thus, both long-acting GLP-2 analogs and DP IV inhibitors have been found to prolong the intestinotrophic actions of this peptide Hartmann et al. 2000) . More detailed reviews on the biological actions of GLP-2 have been written by L'Heureux and Brubaker (2001) and Drucker (2001) .
Secretion of GLP-1 and GLP-2 in health and disease: in vivo studies
Plasma levels of bioactive GLP-1 and GLP-2 in normal, fasting humans are 5-10 and 15-20 pmol/L, respectively (Xiao et al. 1999; Vilsboll et al. 2001) . It is important to note that although many assays exist to determine the circulating concentrations of these peptides, only assays that measure the intact N-terminal sequences of GLP-1 and GLP-2 are able to quantify the biologically active moieties, because of the rapid inactivation of the peptides in the circulation by DP IV. Furthermore, because of the complex nature of proglucagon processing, assays that are directed towards the mid-sequence of either GLP-1 or GLP-2 may also cross-react with the major proglucagon fragment (Fig. 1) . Similarly, assays in which the levels of glicentin or oxyntomodulin are determined must be considered in the light of potential cross-reactivity with the pancreatic PGDPs, glicentin-related pancreatic peptide, and (or) glucagon. Thus, caution should be taken in interpreting the results of radioimmunoassays and ELISAs for the intestinal PGDPs, as the results are highly dependent upon the specificity of the antiserum used. Nonetheless, such studies have provided important information about the factors that regulate secretion by intestinal L cells, and results from these studies will be discussed as appropriate.
The major physiological stimulus to L cells is nutrient ingestion, with circulating levels of the bioactive glucagon-like peptides rising by two-to threefold in response to a mixed meal in humans (Xiao et al. 1999; Vilsboll et al. 2001) . Simple carbohydrates and fats also stimulate GLP-1 and GLP-2 secretion, although protein does not appear to do so, at least in vivo in humans (Morgan et al. 1993; Xiao et al. 1999 ). The secretion profile for both of these peptides is biphasic, with an early peak approximately 30 min after nutrient ingestion and a second, more prolonged peak at 60-120 min (Morgan et al. 1993; Xiao et al. 1999; Rask et al. 2001) . That L cells respond to nutrients is not unexpected, as numerous immunohistochemical studies have demonstrated that they are "open" type epithelial cells that make contact with the luminal contents at their apical surfaces (Eissele et al. 1992 ). However, L cells are localized predominantly in the distal gut (ileum and colon) (Eissele et al. 1992) , and studies in animals have demonstrated that nutrients do not reach these sections of the intestine within the first 30 min after ingestion (Ferraris et al. 1990; Fu-Cheng et al. 1997) . Furthermore, although a recent study has suggested that limited numbers of L cells are present in the proximal gut (Mortensen et al. 2003) , removal of the gut distal to the duodenum in rats completely abrogates the L-cell response to proximal nutrients (Roberge et al. 1996) . These findings therefore led to the suggestion that the stimulus for the early postprandial peak of GLP-1 and GLP-2 is mediated indirectly through a neuroendocrine pathway, whereas direct contact of luminal nutrients with L cells is likely to induce the later peak of secretion (Roberge and Brubaker 1991) . The mechanisms underlying the direct and indirect regulation of secretion by L cells are discussed separately, below.
Secretion of the GLPs is abnormal in a number of different disease states. Circulating levels of both GLP-1 and GLP-2 are elevated in insulin-deficient rodents and in humans with poorly controlled type 1 diabetes (Fischer et al. 1997; Hiroyoshi et al. 1999) . In contrast, secretion is impaired in patients with type 2 diabetes (Mannucci et al. 2000; Vilsboll et al. 2001) . The underlying mechanism for this is currently unknown, although one study has linked insulin resistance to decreased GLP-1 secretion (Rask et al. 2001) . Recent studies have also demonstrated that GLP-1 secretion is reduced in obesity (Ranganath et al. 1999; Verdich et al. 2001) , as discussed in more detail below. Furthermore, removal of the distal gut reduces secretion of the GLPs, consistent with the localization of L cells in the ileum and colon (Robertson et al. 1999; Jeppesen et al. 1999) . Finally, it has been demonstrated that circulating levels of GLP-2 are elevated in patients with active inflammatory bowel disease (Xiao et al. 2000) . These changes occurred in association with decreased plasma DP IV activity, indicating that alterations in degradation of the GLPs affect their circulating concentrations. Similarly, studies have demonstrated increased concentrations of GLP-1 and GLP-2 in patients and rodents with impaired renal function (Orskov et al. 1992; Tavares et al. 2000) , suggesting a role for the kidney in the clearance of these peptides.
Indirect regulation of GLP-1 and GLP-2 secretion by proximal nutrients
The evidence for involvement of the nervous system in the early peak of nutrient-induced GLP-1 and GLP-2 secretion is compelling. Early studies conducted in rodents demonstrated that the placement of fat into a ligated duodenal segment (to prevent nutrient flux to the distal intestine) stimulates secretion by the distal L cells Brubaker 1991, 1993) . Control experiments with vehicle confirmed that the effect was not caused by distension of the lumen, but rather was nutrient dependent. Similar stimulation of two other distal enteroendocrine hormones, neurotensin and peptide YY, in response to proximal nutrients has also been reported (Greeley et al. 1989; Miyashita et al. 1992; Fu-Cheng et al. 1997) . These initial studies therefore strongly implicate the nervous system in mediating the early peak of GLP-1 and GLP-2 secretion in response to nutrient ingestion (Fig. 2) . Consistent with these findings, subsequent studies have shown that bilateral subdiaphragmatic vagotomy prevents stimulation of rat L cells by duodenal fat, while direct activation of the celiac branch of the vagus increases secretion (Rocca and Brubaker 1999) . The early rise in GLP-1 in response to nutrients is also blocked by infusion of atropine in both rodents and humans (Balks et al. 1997; Anini et al. 2002) . Although human and rodent L cells express M1, M2, and M3 muscarinic receptors (Anini et al. 2002; Anini and Brubaker 2003a) , treatment in vitro with agonists of M1 (e.g., McN-A-343) but not M3 (e.g., Oxotremorine-M) muscarinic receptors increases GLP-1 secretion. Additionally, stimulation of L cells by bethanechol (a nonspecific muscarinic agonist) is prevented by antagonists for the M1 and M2 (e.g., Pirenzipine and Gallamine, respectively) but not M3 (e.g., 4-DAMP) receptor subtypes (Anini et al. 2002; Anini and Brubaker 2003a) . However, only the M1 receptor antagonist also blocks the effects of proximal nutrients on L cells in rats in vivo (Anini et al. 2002) . Interestingly, M1 muscarinic receptors signal through phospholipase C and calcium (Eglen et al. 2001 ), a pathway that is known to stimulate secretion by L cells (Anini et al. 2002; Anini and Brubaker 2003a) . We have therefore proposed that proximal nutrients activate vagal afferents that through the efferent celiac branch stimulate M1-subtype muscarinic-receptor-dependent GLP-1 secretion (Fig. 2) . Other studies have also implicated nicotinic receptors (Anini et al. 1999) , as well as the enteric neuropeptide gastrin-releasing peptide (GRP) (Brubaker 1991; Hermann-Rinke et al. 1995; Roberge et al. 1996; Persson et al. 2000) in this pathway, suggesting the additional involvement of multiple connecting interneurons between the vagus nerve and the L cells. Finally, it also remains to be established whether any of the effects of muscarinic agonists or antagonists on GLP-1 secretion observed in vivo might also be exerted through a central mechanism.
Despite the clear evidence for vagal control of GLP-1 secretion, the mechanism by which nutrients activate the afferent component of this pathway remains unclear. Nutrient-sensitive vagal afferents have been detected in rodents (Zhu et al. 2001) . However, the duodenum also releases a number of endocrine hormones in response to fat and carbohydrate ingestion, of which one, glucosedependent insulinotropic peptide (GIP), is also an L-cell secretagogue in rodents (Brubaker 1991; Brubaker 1993, 1999; Dumoulin et al. 1995; Rocca and Brubaker 1999) . Interestingly, infusion of GIP into rats at a low, "physiological" dose stimulates L cells in a vagal-dependent fashion, while supraphysiological doses of GIP increase GLP-1 secretion in both normal and vagotomized animals (Rocca and Brubaker 1999) . Similarly, dose-response studies with GIP using rat L cells in vitro, as well as perfused rat ileum in situ, have demonstrated that relatively high concentrations (≥10 -10 mol/L) are required to stimulate secretion (Brubaker 1991; Dumoulin et al. 1995) . Similar dose-dependent direct, as well as indirect, vagally mediated effects have also been reported for the actions of the intestinal hormone cholecystokinin on rat exocrine pancreatic secretion (Li and Owyang 1993) . Thus, in the normal rat, nutrient-induced release of GIP appears to stimulate L cells indirectly through the vagus nerve, although higher levels of GIP can also exert direct effects on L cells. These direct effects of GIP are likely mediated through protein kinase A (Gremlich et al. 1995) , a signaling pathway known to increase secretion of the GLPs (Brubaker 1991) . When taken together, therefore, these findings provide further evidence for the important role of the vagus in mediating the early rise in GLP-1 and GLP-2 secretion in response to duodenal nutrient loads in rats.
Although the data from humans clearly indicate a role for cholinergic mediation of the early peak of GLP-1 secretion (Balks et al. 1997) , it remains to be established whether this pathway is mediated directly, through vagal sensing of duodenal nutrients, or indirectly, through an endocrine or other mediator. Studies with GIP to date have failed to demonstrate an L-cell response in humans in vivo (Nauck et al. 1993) , and indeed no duodenal hormone has been identified to date that can stimulate human L cells. Nonetheless, there is some evidence that the enteric neuropeptide GRP does stimulate human L cells (Reimer et al. 2001 ). Thus, regulation of human L cells appears to exhibit both similarities to and differences from rodent L cells with respect to the mechanisms underlying the early response to ingested nutrients.
Direct regulation of GLP-1 and GLP-2 secretion by luminal nutrients
A number of studies have demonstrated direct effects of nutrients on distal L cells, suggesting that such actions are responsible for the late rise in GLP-1 and GLP-2 secretion after nutrient ingestion. Although fats, carbohydrates, and protein can all stimulate L cells when applied directly, it must be kept in mind that the products of carbohydrate and protein digestion do not normally transit to the distal regions of the small intestine and, thus, the physiological relevance of the direct effects of these nutrients on L cells remains unclear.
Administration of a fatty-acid mixture directly into the ileum of rats stimulates secretion by L cells Brubaker 1991, 1993; Dumoulin et al. 1998; Rocca and Brubaker 1999) , and fatty acids stimulate L cells directly when applied in vitro (Rocca and Brubaker 1995) . The actions of fatty acids on L cells are highly specific, such that only monounsaturated fatty acids (MUFA) with 16 or more carbons and a free carboxyl group are stimulatory to rodent L cells in vitro (Rocca and Brubaker 1995) . Consistent with these findings, administration of a diet containing only olive oil as the fat (i.e., enriched in MUFA) increases GLP-1 secretion in rats as compared with a diet containing only coconut oil as the fat (i.e., enriched in saturated fat) (Rocca et al. 2001) , and release of GLP-1 in humans is increased by MUFA to a greater extent than by saturated fat (Beyse et al. 2002) . The mechanism by which fatty acids exert their effects on L cells remains unclear. However, recent studies have indicated that L cells contain the intestinal isoform of the fatty-acid binding protein (iFABP), as well as PKCζ, both of which have been implicated in fatty-acid signaling (Rocca et al. 2001) .
Direct application of glucose to the luminal surface of the ileum stimulates L cells in rats and humans (Roberge and Brubaker 1993; Layer et al. 1995) , although this effect has not been observed with rat or canine L cells in vitro (V. Wong and P.L. Brubaker, personal communication; Damholt et al. 1998) . Nonetheless, administration of an α-glucosidase inhibitor that delays sucrose digestion and therefore allows transit into the distal gut does enhance GLP-1 release (Qualmann et al. 1995; Seifarth et al. 1998) . Furthermore, a recent study utilizing a murine intestinal L-cell line has now demonstrated that glucose and other metabolizable sugars enter the L cell (likely via a glucose transporter, GLUT1 or GLUT5) and induce depolarization by closure of K ATP channels (Kir6.2/SUR1) (Reimann and Gribble 2002) . Furthermore, consistent with its intestinal epithelial origin, the L-cell line is also activated by entry of electrogenic carbohydrates (likely via a sodium-glucose luminal transporter, SGLT1 or SGLT3) (Gribble et al. 2003) . This latter finding is also consistent with reports that luminal glucose stimulates L cells in a sodium-dependent fashion (Sasaki et al. 1993) . Thus, the direct effects of carbohydrates on GLP-1 secretion may be mediated through two different mechanisms, although it must be noted that these findings remain to be confirmed in a primary L-cell model.
Finally, protein meals do not increase GLP-1 or GLP-2 levels in vivo in humans (Morgan et al. 1993; Xiao et al. 1999) . However, application of peptones directly into the ileum has been reported to stimulate GLP-1 release in rats (Plaisancié et al. 1995) , although not in humans (Layer et al. 1995) , while a meat hydrolysate stimulates GLP-1 secretion from a rodent intestinal L-cell line (Reimer et al. 2001 ). Finally, ingestion of an amino acid mixture stimulates GLP-1 release in humans (Herrmann et al. 1995) , but amino acids do not affect secretion by primary rat L cells (P.L. Brubaker, personal communication). The physiological effects of ingested protein and its digestion products on L cells therefore remain to be clearly established.
Other factors that regulate GLP-1 and GLP-2 secretion
Although a number of different neuroendocrine hormones have been reported to modulate secretion of the GLPs (Brubaker 1991; Dumoulin et al. 1995; Hermann-Rinke et al. 1995) , only a few have been studied in any detail. The first of these is the intestinal hormone somatostatin, and the second is the satiety hormone leptin.
In vivo studies in both humans and rats have demonstrated that infusion of somatostatin-14 inhibits secretion by L cells (Bloom and Polak 1982; Fuessl et al. 1987) . Initial in vitro studies conducted on the two molecular forms of somatostatin (SS) found in the intestine, SS-14 and SS-28, demonstrated that both peptides inhibit L cells in a PKA-dependent fashion, with the enteroendocrine SS-28 being more potent than the neural SS-14 in mediating this effect (Brubaker 1991; Chisholm and Greenberg 2002) . Studies on the rat L cell have demonstrated that these actions of SS-28 on L cells are exerted through SS receptor subtype 5 (Chisholm and Greenberg 2002) . As GLP-1 also stimulates release of SS-28 from the intestine (Brubaker et al. 1997a) , it has now been suggested that secretion by L cells is autoregulated through interactions between GLP-1 and SS-28 (Brubaker et al. 1997a; Chisholm and Greenberg 2002) .
As noted previously, both basal and postprandial GLP-1 levels are reduced in patients with obesity (Ranganath et al. 1999; Verdich et al. 2001) . Because increased leptin secretion from adipocytes, as well as central nervous system (CNS) leptin resistance, are common features of obesity, it was hypothesized that leptin stimulates L cells and, thus, that leptin resistance contributes to the reduced GLP-1 secretion observed in obesity (Anini and Brubaker 2003b) . Using in vivo rodent models as well as in vitro human, murine, and rat L-cell lines, leptin was demonstrated to activate the signal transducer and activator of transcription-3 (STAT3) signaling pathway, as well as to increase secretion of GLP-1 in a dose-dependent fashion (Anini and Brubaker 2003b) . Furthermore, induction of diet-induced obesity in mice reduces both basal and oral glucose-stimulated GLP-1 secretion in association with leptin resistance. Leptin is normally considered to be a hormone of adipocyte origin that is constitutively released into the circulation (Friedman and Halaas 1998) , suggesting that its stimulatory effects on L cells may be tonic. However, recent studies have demonstrated that leptin is also released into the intestinal lumen by cells of the duodenum in response to nutrient ingestion, where it regulates secretion of cholecystokinin (Guilmeau et al. 2003) . It therefore remains to be established whether leptin-induced stimulation of L cells is mediated via luminal and (or) circulating leptin.
Summary
GLP-1 and GLP-2 play key roles in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. The regulation of GLP-1 and GLP-2 secretion by ingested fat and carbohydrate is complex, involving indirect vagal pathways as well as direct stimulation of the distal intestinal L cells. These complex mechanisms result in a biphasic pattern of secretion that, presumably, optimizes the biological actions of these important intestinal hormones.
